What are the most awaited trials of #TCT2022?

In this engaging episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) review the most impactful late-breaking science studies from TCT 2022. 

Trials covered in detail include:
00:35:49  PROTECTED TAVR 
2:13:00 CLASP II D 
4:30:22 TVT Registry
6:18:47 The United Kingdom National Registry 
7:30:02: Amulet IDE
10:22:45 SCOPE I 
12:38:00 RADIANCE II Pivotal Trial 
14:42:43 SYMPLICITY HTN-3 
16:28:28 Pulmonary Artery Denervation for Pulmonary Arterial Hypertension 
17:38:29 UNIVERSAL
19:54:26 FLASH Registry  
21:56:10 BEST 
24:06:37 FAVOR III China